- Home
- PETS vs ADVM Comparison
PETS vs ADVM Comparison
Compare PETS & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ADVM
- Stock Information
- Founded
- PETS 1996
- ADVM 2006
- Country
- PETS United States
- ADVM United States
- Employees
- PETS N/A
- ADVM N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PETS Consumer Staples
- ADVM Health Care
- Exchange
- PETS Nasdaq
- ADVM Nasdaq
- Market Cap
- PETS 118.8M
- ADVM 119.6M
- IPO Year
- PETS N/A
- ADVM 2014
- Fundamental
- Price
- PETS $5.58
- ADVM $5.23
- Analyst Decision
- PETS Sell
- ADVM Strong Buy
- Analyst Count
- PETS 2
- ADVM 6
- Target Price
- PETS $3.50
- ADVM $27.83
- AVG Volume (30 Days)
- PETS 296.2K
- ADVM 286.5K
- Earning Date
- PETS 02-06-2025
- ADVM 11-04-2024
- Dividend Yield
- PETS N/A
- ADVM N/A
- EPS Growth
- PETS N/A
- ADVM N/A
- EPS
- PETS N/A
- ADVM N/A
- Revenue
- PETS $259,343,000.00
- ADVM $1,000,000.00
- Revenue This Year
- PETS N/A
- ADVM N/A
- Revenue Next Year
- PETS $3.36
- ADVM N/A
- P/E Ratio
- PETS N/A
- ADVM N/A
- Revenue Growth
- PETS N/A
- ADVM N/A
- 52 Week Low
- PETS $2.90
- ADVM $4.97
- 52 Week High
- PETS $7.79
- ADVM $29.70
- Technical
- Relative Strength Index (RSI)
- PETS 56.24
- ADVM 30.15
- Support Level
- PETS $5.41
- ADVM $5.65
- Resistance Level
- PETS $6.85
- ADVM $6.07
- Average True Range (ATR)
- PETS 0.45
- ADVM 0.36
- MACD
- PETS -0.01
- ADVM -0.05
- Stochastic Oscillator
- PETS 48.37
- ADVM 12.94
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.